Search

Displaying results 1701 - 1710 of 7604 in total
  1. Drug

    Denileukin diftitox

    go.drugbank.com/drugs/DB00004
    ApprovedInvestigational

    approved to treat a human disease in the US. … >387</sub>)-His and the sequence for human interleukin-2 (IL-2; Ala<sub>1</sub>-Thr<sub>133</sub>).

  2. Drug

    Canrenoic acid

    go.drugbank.com/drugs/DB09015
    ApprovedInvestigationalWithdrawn

    Canrenoic acid (as the salt potassium canrenoate) is an aldosterone antagonist. Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body.

  3. Drug

    Oxcarbazepine

    go.drugbank.com/drugs/DB00776
    ApprovedInvestigational

    Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000. … [A186011] Compared to other anti-epileptic drugs, which are generally metabolized via the cytochrome P450 system, oxcarbazepine has a reduced propensity for involvement in drug-drug interactions owing

  4. Drug

    Sulfadoxine

    go.drugbank.com/drugs/DB01299
    ApprovedInvestigationalWithdrawn

    A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.

  5. Drug

    Berdazimer

    go.drugbank.com/drugs/DB18712
    Approved

    [A262965] On Jan 05, 2024, the FDA approved berdazimer under the brand name ZELSUVMI for the treatment of adult and pediatric molluscum contagiosum, and it is the first drug to be approved for this … [A262960] Berdazimer was previously investigated as a potential treatment for molluscum contagiosum, a viral cutaneous infection mainly affecting children, sexually active adults, and immunocompromised

  6. Drug

    Tilactase

    go.drugbank.com/drugs/DB13761
    ApprovedInvestigational

    [A32591] It is considered by the WHO as part of the International Nonpropietary Names for Pharmaceutical Substances.[L2338] … [A27172] The beta-D-galactosidase us a large monomeric multi-domain enzyme of 985 residues that presents a catalytic (alpha/beta)8-barrel domain.

    Products: LACDIGEST 2250 U CIGNEME TABLETI, 100 TABLET, LACDIGEST 2250 U CIGNEME TABLETI, 50 TABLET
  7. Drug

    Vorasidenib

    go.drugbank.com/drugs/DB17097
    ApprovedInvestigational

    [A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144]

  8. Drug

    Nilutamide

    go.drugbank.com/drugs/DB00665
    ApprovedInvestigational

    Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). … Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.

  9. Drug

    Givosiran

    go.drugbank.com/drugs/DB15066
    Approved

    [L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder … involved non-therapeutic measures (e.g. trigger avoidance), intravenous [hemin] for the treatment of attacks, and liver transplantation in refractory cases.

  10. Drug

    Pafolacianine

    go.drugbank.com/drugs/DB15413
    ApprovedInvestigational

    [L39332] The longer wavelength allows for deeper penetration of the fluorescent light through tissues for better imaging and detection of tumours. … [A242572] On November 29, 2021, the FDA approved pafolacianine as an adjunct imaging agent for intraoperative identification of malignant lesions in adult patients with ovarian cancer.

    Categories: Compounds used in a research, industrial, or household setting